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Abstract
Oxidative stress is related to ageing and degenerative diseases, including cancer. However, a moderate amount of
reactive oxygen species (ROS) is required for the regulation of cellular signalling and gene expression. A low level of
ROS is important for maintaining quiescence and the differentiation potential of haematopoietic stem cells (HSCs),
whereas the level of ROS increases during haematopoietic differentiation; thus, suggesting the importance of redox
signalling in haematopoiesis. Here, we will analyse the importance of ROS for haematopoiesis and include evidence
showing that cells from leukaemia patients live under oxidative stress. The potential sources of ROS will be described.
Finally, the level of oxidative stress in leukaemic cells can also be harnessed for therapeutic purposes. In this regard, the
reliance of front-line anti-leukaemia chemotherapeutics on increased levels of ROS for their mechanism of action, as
well as the active search for novel compounds that modulate the redox state of leukaemic cells, will be analysed.
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Background
The emergence of oxygen in the Earth’s atmosphere,
more than 2 billion years ago, was a key event for life on
this planet. The access to oxygen allowed eukaryotic
cells to adopt a more efficient metabolism, which sped
up the evolution of eukaryotes. However, aerobic meta-
bolism also has a dark side: the production of reactive
oxygen species (ROS) by the partial reduction of oxygen.
Some representative examples are superoxide (O2
−),
hydrogen peroxide (H2O2) and hydroxyl radical (OH
−)
[1]. ROS have traditionally been considered toxic
by-products of cellular respiration. They are highly re-
active and are able to modify all kinds of biomolecules
in the cell. For this reason, oxidative stress has been
related to ageing [2] and pathological conditions such as
cancer [3]. However, during the last decades it has been
determined that a moderate production of ROS may be
required for the control of cellular signalling and gene
expression [4]. The term redox signalling is increasingly
used, and should be distinguished from the concept of
oxidative stress.
Quantitatively, the mitochondrion is the most important
source of ROS in the cell. Some enzymatic systems also con-
tributing to ROS production are xanthine oxidoreductase
(XOR), uncoupled NO synthase (NOS), cyclo-oxygenase
(Cox), cytochrome P450 mono-oxygenase, myeloperoxidase
(MPO), lipoxygenase and NADPH oxidases (Nox). Among
these cellular systems, the NADPH oxidase family has ex-
clusively evolved to produce ROS as a primary function [5].
Curiously, the first member of the family, phagocyte oxidase,
was identified in the haematopoietic system. This enzyme
produces large amounts of ROS which are required for
pathogen elimination [5]. Genetic disorders associated with
this oxidase cause chronic granulomatous disease (CGD), an
innate immunity defect characterised by recurrent fungal
and bacterial infections [6]. In addition to Nox2, the catalytic
subunit of the phagocyte oxidase, there are 6 other family
members (Nox1, Nox3, Nox4, Nox5, Duox1 and Duox2).
Duox1 and 2 present a peroxidase-like domain and together
with Nox5 could be activated by calcium [5].
The production of intracellular ROS in response to
growth factors was suggested almost 40 years ago [7]. It
was later observed that low concentrations of H2O2
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induce cell growth [8]. Nowadays, there is a plethora of
evidence showing the importance of ROS production for
cellular signalling in response to growth factors and
other signals [9]. A proportion of ROS is catalytically
generated and eliminated in the cell in response to
extracellular signals. The fact that OH- removes elec-
trons from surrounding biomolecules in an unspecific
manner and O2
− signalling function requires its trans-
formation into H2O2 suggests that H2O2 most likely
plays a role as a true second messenger [10]. On the
basis of this hypothesis, it would be interesting to eluci-
date how specificity is achieved in the context of redox
signalling. It is, however, tempting to speculate about
the formation of a ROS gradient from the source of pro-
duction, where proteins under the influence of such a
gradient would be oxidised, while others out of reach
would be immune to increases in the level of ROS.
To fully comprehend the concept of redox signalling,
it is necessary to understand how ROS influence cellular
signalling and gene expression (Fig. 1). Compelling evi-
dence suggests that the reversible oxidation of specific
amino acids, such as certain cysteine residues, regulates
protein function [10]. Modification of proteins with
reactive cysteines is thought to be a general mechanism
to mediate redox signalling. One of the best known ex-
amples is the family of the protein tyrosine phosphatases
(PTPs). All these proteins are characterised by the
presence of a conserved cysteine residue required for
catalysis [11], which makes them highly susceptible to
oxidation [12]. Reversible oxidation of PTPs has been
suggested as an important mechanism in the regulation
of the activity of these enzymes in vivo [13].
The list of signalling proteins regulated through oxidation
is continuously growing. Serine/threonine phosphatases
can be inhibited [14], kinases are subject of either activation
or inhibition [15] and the activity of Rac1 [16] and RhoA
[17] GTPases is reported to be increased when key amino
acids are oxidized.
There is also a complex cross-talk between ROS and
Ca2+ levels. Calcium channels seem to be regulated by
redox mechanisms in different subcellular locations and,
concomitantly, ROS production by NADPH oxidases
and mitochondria may be induced by calcium [18].
The list of transcription factors, such as AP-1, p53,
NF-κB, or HIF1α, whose DNA binding affinity can be
inhibited by oxidation, is also growing. The AP endonucle-
ase 1/redox factor 1 (APE1/Ref-1) complex, involved in
base excision repair, keeps transcription factors in a
reduced active state [19]. ROS have also been shown to
regulate the accumulation of transcription factors in the
nucleus, such as the Forkhead box protein O 4 (FOXO4)
[20] and nuclear factor erythroid 2-related factor 2 (Nrf2)
Fig. 1 General landscape of redox singnalling. Here we present the main molecular targets of ROS described to date: classical signalling proteins,
such as kinases, phosphatases or small GTPases; transcription factors and epigenetic modullators; and calcium fluxes, with which there exists a
complex cross-talk (see text). Red arrows mean inhibition of the target or process; green arrows mean activation; blue arrow with ‘~’ symbol
means that both activation and inhibition can be achieved depending on the specific target. Dotted lines indicate propose or not empirically
demonstrated relationship
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[21]. Interestingly, FOXOs and Nrf2 participate in cellular
response to oxidative stress, since they have the ability to
bind ARE (antioxidant response elements) and activate the
expression of antioxidant and detoxifying enzymes. The
activity of epigenetic modifiers, such as some histone dea-
cetylases (HDACs), can also be inhibited by oxidation [22].
Redox signalling in haematopoiesis
Haematopoiesis constitutes one of the paradigms of
cell differentiation, since a single cell type, the haem-
atopoietic stem cell (HSC), gives rise to all mature
blood lineages. Unlike other differentiation processes
restricted to embryonic development, blood cell pro-
duction continues to occur throughout the entire life
cycle. To ensure correct haematopoiesis, the balance
between differentiation and self-renewal in HSCs
must be strictly regulated [23]. Moreover, the use of
HSCs in regenerative medicine is noteworthy, and a
better understanding of HSCs biology could contri-
bute to improving their usefulness.
The niche contributes to the maintenance of a low level
of ROS in HSCs
Compelling evidence suggests that ROS are important to
regulate the balance between self-renewal and differenti-
ation of adult stem cells. A low level of ROS would contrib-
ute to maintaining the pluripotency of these cells, whereas
a higher amount would commit them to a restricted lineage
[24]. In adults, HSCs reside and differentiate in bone
marrow (BM), where different cell types, soluble factors
and anatomical structures collaborate to maintain their
characteristics. This complex environment is generally
known as the niche [25], where different regions have been
distinguished: the endosteal niche, defined by the osteo-
blasts; the vascular niche, composed by BM sinusoidal
endothelial cells (BMSECs); and the perivascular niche,
where CXC chemokine ligand 12 (CXCL-12)-abundant re-
ticular cells (CAR cells) and Nestin+ mesenchymal stem
cells are present [26]. Apart from comprising different cell
types, a fundamental difference among these niches is ac-
cess to oxygen, which should be more readily available
within the vascular and perivascular niche than in the
endosteal niche.
The accepted idea is that most quiescent HSCs remain
under hypoxic conditions in BM [24]. A more restricted
access to oxygen would result in lower ROS content,
which could have relevant functional consequences. A
seminal contribution by Jang and Sharkis showed that a
high level of ROS is detrimental for HSCs function [27].
They characterized two different HSC populations ac-
cording to the intracellular levels of ROS. The ROSlow
population showed greater quiescence and self-renewal
potential, while in the ROShigh population the haemato-
poietic reconstitution capacity was hampered. They also
suggested that the ROSlow population is located within
the endosteal niche, where cells have less oxygen avail-
ability and therefore lower levels of intracellular ROS.
This situation would promote their quiescence and
maintain their reconstitution capacity. In addition to
their location, some work has highlighted the relevance
of niche cells in the maintenance of a reduced ROS con-
centration in HSCs through a transference of ROS from
these cells to BM stromal cells [28].
HSCs receive multiple stimuli from the surrounding
niche that influence their ability to remain quiescent,
undergo self-renewal or differentiate. One of the most
important signals is the stromal cell-derived factor-1
(SDF-1, also named CXCL12) which binds to the
CXCR4 receptor in HSCs. CXCL12 belongs to a large
family of chemoattractive cytokines that act through
G-protein-coupled receptors. This cytokine is produced
by CAR cells in the bone marrow niche, and was origin-
ally described as being involved in the proliferation of B
cell precursors. Later on its essential role for HSCs
homing was discovered [29]. The CXCL12/CXCR4 axis
regulates important processes such as homing, quies-
cence/proliferation or migration in these cells. Interes-
tingly, protection against oxidative stress has recently
emerged as an important mechanism of CXCL12/
CXCR4 signalling in the maintenance of HSCs homeo-
stasis [30]. As recently reviewed, the alteration of this
signalling pathway may contribute to leukaemogenesis
[31]. In addition to its involvement in haematopoiesis,
CXCL12/CXCR4 signalling is required for stem cell mi-
gration and homing in other developmental processes,
such cardiogenesis, angiogenesis and neurogenesis [29],
and also for cancer cell migration and metastasis [32].
Intrinsic factors that control ROS levels in HSCs
Several reports suggest that the most primitive HSCs,
those with the capacity for long-term reconstitution
(LT-HSCs), are located at the endosteal niche, where
they can face hypoxic conditions [33]. The lack of oxygen
requires for them to adopt an anaerobic metabolism,
which is linked to a decrease in ROS production [24].
However, there are some reports suggesting that the
reduced ROS content in HSCs is independent of their
anatomical location [34]. Therefore, besides localization
within BM niches, there must be intrinsic factors that con-
tribute to maintaining the low levels of ROS detected in
HSCs. As will be discussed later on, some of these factors
have been revealed through gene-targeting experiments in
mice, where HSCs are shown to have an increased level of
ROS and an impaired functionality.
Hypoxia inducible factor 1 (HIF-1) is a transcription
factor essential for the adaptation to low O2 pressure.
HIF-1 is a heterodimeric protein that consists of a con-
stitutively expressed subunit (HIF-1β) and an inducible
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subunit (HIF-1α) stabilised upon hypoxic conditions.
Under normoxia, HIF-1α hydroxylation targets the pro-
tein for degradation [35]. Stabilization of HIF1α in HSCs
seems to be important for maintaining the correct level
of ROS. It has been described how the lack of HIF1α in
HSCs leads to increased ROS production, which is
related to overproliferation, engraftment defects, loss of
stemness and senescence [36]. The expression of HIF1α
can promote anaerobic metabolism instead of mitochon-
drial oxidative phosphorylation in HSCs [37]. This fact,
together with reduced mitochondrial activity [24], would
lead to the limited production of ROS in these cells.
There is increasing evidence showing that the Fork-
head O (FoxO) subfamily of transcription factors plays
an important role in the preservation of a low level of
ROS in HSCs, which protects them from oxidative
stress. The deletion of FoxO1, FoxO3 and FoxO4 in the
hematopoietic system leads to a dramatic decrease in
the number of HSCs, an increase of their cycling, and
the expansion of myeloid lineage cells. Moreover, their
reconstitution capacity is severely disrupted. These ef-
fects correlate with a significant increase in ROS in the
HSCs compartment; therefore, antioxidant treatment
could rescue the phenotype [38]. In agreement with
these findings, the deletion of FoxOs is reported to re-
duce HSCs quiescence and to impair their self-renewal
capacity as a consequence of the ROS-dependent
activation of the p38 mitogen-activated protein kinase
(MAPK) cascade [39].
The protein encoded by the ataxia–telangiectasia
mutated gene (Atm) coordinates the cellular response to
protect genomic stability against damage such as geno-
toxic and oxidative stress or DNA double strand breaks.
Mutant variants of this gene cause ataxia telangiectasia
[40], a disease characterised by severe neurological de-
fects, and increased risk of developing T-and B-cell
lymphomas and leukaemias [41]. There is evidence sug-
gesting that Atm gene plays a role in maintaining a low
level of ROS in HSCs. Atm loss correlates with a ROS
increase in HSCs and the activation of the p38 MAPK
cascade, which reduces the lifespan and the quiescence
of HSCs. Interestingly, treatment with antioxidants or
p38 inhibitors alleviates these effects [42].
Previous work has shown that p53 stabilization is re-
quired to avoid the exhaustion of HSCs upon oxidative
stress [43]. However, this is a complex situation, since
p53 accumulation can also lead to an increase in ROS;
thus, initiating a vicious cycle that induces HSCs cell
cycle arrest, senescence and eventually cell death [44].
Polycomb group (PcG) proteins are implicated in tran-
scriptional repression through histone modifications,
and are known to control the self-renewal of stem cells
[45]. Deletion of one member of this family, Bmi1,
induces premature HSCs senescence and deficient
self-renewal [46]. These effects could be related to an
increase in ROS. Also, it should be noted that Bmi1 can
regulate mitochondrial ROS production [47].
Furthermore, the overall ROS levels in cells are a
result of the balance between their generation and eli-
mination. Although more work is still required to
further understand the relevance of this relationship, it
could be assumed that the activity of the cellular antioxi-
dant systems is necessary for maintaining the low levels
of ROS observed in HSCs [48].
Redox signalling and the haematopoietic differentiation
HSCs are influenced by numerous cytokines, growth fac-
tors and other soluble factors that instruct their
self-renewal, proliferation, differentiation or migration
within the different niches. It has long been known that
haematopoietic cytokine signalling is accompanied by
ROS formation [49]. It has also been described that the
levels of ROS in myeloid progenitors are higher than in
HSCs [38], and that an increase in ROS triggers myeloid
differentiation in animal models [50]. Some results have
shown the importance of a moderate increase in ROS
for the megakaryocytic differentiation of human HSCs
[51]. More recently, a progressive increase in ROS dur-
ing HSCs differentiation has been described [52]. Bear-
ing the aforementioned in mind, the importance of
redox signalling for haematopoiesis is unquestionable.
Thus, the signalling pathways regulating haematopoiesis
susceptible to redox regulation should be delineated. In
the following paragraphs the possibilities regarding this
association will be discussed.
An increase of ROS during haematopoietic cytokine
signalling is necessary for the complete activation of the
pathways that lead to differentiation, including AKT
[51]. The phosphoinositide 3-kinase (PI3K)/AKT/mTOR
(mammalian target of rapamycin) pathway is a good
example illustrating that an appropriate level of ROS is
essential for haematopoiesis. Simultaneous deletion of
AKT1 and AKT2 greatly increases the quiescence of
HSCs to the point of impairing their long-term reconsti-
tution capacity [53]. This failed haematopoiesis corre-
lates with a significant decrease in the ROS content of
HSCs. However, the application of exogenous ROS could
rescue the differentiation capacity of AKT1 and AKT2
deficient HSCs in vitro. On the contrary, constitutive
AKT activation increases HSCs cell cycling and leads to
leukaemogenesis [54]. Therefore, a proper supply of
redox signalling is important for the appropriate activa-
tion of AKT, which in turn is involved in maintaining
the correct level of ROS for HSCs differentiation.
The deletion of tuberous sclerosis complex (TSC) gene
product TSC1 suggests that mTOR inactivation re-
presses mitochondrial biogenesis, which would maintain
low levels of ROS in the HSCs compartment [55].
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The MAPK pathways are involved in the transmission
of a great variety of extracellular signals, including those
regulating haematopoiesis [56]. MAPK activation can
sometimes be dependent on ROS production [57]. A sus-
tained activation of the MEK/ERK pathway by thrombo-
poietin (TPO) is observed during megakaryocytic
differentiation [58]. The complete activation of the MEK/
ERK pathway depends on a moderate increase in ROS
production [51]. As mentioned above, the p38 MAPK
pathway can be aberrantly activated by oxidative stress,
thus impairing HSCs function and engraftment [42, 59].
Given the susceptibility of PTPs to oxidation, these
enzymes could be involved in the redox control of
haematopoiesis. As recently shown, SHP1 oxidation is
required for T cell development [60]. Gain-of-function
mutations in the PTPN11 gene, encoding SHP2, lead
to Noonan syndrome, juvenile myelomonocytic leu-
kaemia (JMML), myelodysplastic syndrome, B cell
ALL, and AML. Some of these mutations have been
shown to induce an increase in cellular ROS, which
could alter the redox signalling balance and be related
to the pathogenicity [61].
Canonical Wnt signalling promotes β-catenin stabilisa-
tion, and has been related to the control of HSCs
homeostasis [62]. β-catenin levels are important for
regulating HSCs quiescence and the interaction with the
BM niche [63]. It has been shown that Wnt/β-catenin
can be under redox regulation by nucleoredoxin [64].
Moreover, β-catenin levels are controlled by the protein
tyrosine phosphatase PTPN13 [65]. Taking all these facts
into consideration, it is tempting to speculate that the
Wnt/β-catenin signalling could be a target of ROS
during haematopoiesis.
Oxidative stress and redox signalling in
leukaemia
Since leukaemogenesis is a multistep process, it is diffi-
cult to identify a single driving force. Mutations affecting
oncogenes, DNA repair genes and tumour suppressor
genes may be some of the causes of leukaemogenesis.
Such mutations would confer a proliferative advantage
to leukaemic cells and a way to avoid differentiation
[66]. With the discovery of oncogenes, a great deal of
cancer research has been focused on their alterations,
disregarding other cellular processes such as the meta-
bolic changes that occur during tumour transformation.
Nowadays, the implication of the metabolic reprogram-
ming exhibited by leukaemic cells is receiving much at-
tention [67]. It has long been known that increased
production in ROS is one of the defining characteristics
of tumour cells [68], and leukaemic cells are no excep-
tion, as they also exhibit elevated level of ROS. This fea-
ture has been observed in numerous leukaemic cell lines
and also in the cells from patients with different types of
leukaemia, such as chronic myeloid leukaemia (CML)
[69, 70], acute myeloid leukaemia (AML) [71], T-cell
acute lymphoblastic leukaemia (T-ALL) [72], acute
lymphocytic leukaemia (ALL) [73], chronic lymphocytic
leukaemia (CLL) [74], and in myeloproliferative neo-
plasms (MPNs) [75]. Therefore, it is generally accepted
that increased ROS production is important for the
progression of haematological malignancies [76, 77].
In this section some of the conditions that might
explain the situation of oxidative stress with respect to
leukaemic cells will be analysed. Moreover, we will delve
into the relationship between leukaemia-related onco-
genes and oxidative stress.
Sources of ROS in leukaemia
Haematopoietic cytokine signalling occurs in parallel
with an increase in ROS production [49]. It has been
shown that TPO elicits ROS production in human
HSCs, an event required for their differentiation [51].
The results of other laboratories are in agreement with
this finding, thus highlighting the relevance of NADPH
oxidases for megakaryopoiesis [78]. Recent reports
suggest the implication of NADPH oxidases in the
differentiation of other haematopoietic lineages such as
macrophages [79] or granulocytes [80]. Different Nox
isoforms are found in haematopoietic cells with expres-
sion patterns that may vary among the different lineages
[81]. Taken together, these data support the idea that
NADPH oxidase-driven ROS production is important
for haematopoiesis.
Compelling evidence also illustrates the importance of
NADPH oxidases as a source of ROS in leukaemia.
Their enzymatic activity appears to be required for cell
proliferation in AML patients [71]. The presence of a
truncated form of the granulocyte colony-stimulating
factor (G-CSF) receptor is associated with a high risk of
developing AML. Interestingly, this defective receptor
induces an increase in ROS through NADPH oxidases,
which could be assumed to be related to disease pro-
gression [82]. It seems that Nox2 activity could account
for the immunoresistance of chronic myelomonocytic
leukaemia (CMML) [83] and CML cells [84]. There are
two different reports that link Nox5 activity with two
types of lymphoid leukaemia. Kamiguti et al. suggest that
Nox5-generated ROS contribute to the activation of
malignant B cells in hairy cell leukaemia through the
inactivation of SHP1 [85]. In addition, another report
supports the requirement of Nox5 for cell transform-
ation driven by the human T-cell leukaemia virus type 1
(HTLV-1), which is associated with the development of
adult T-cell leukaemia (ATL) [86].
Although HSCs exhibit low mitochondrial metabolism,
recent work suggests the importance of mitochondrial
function for their survival [87] and self-renewal [88].
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Mitochondrial biogenesis is activated as HSCs differentiate
[89]. Additionally, their metabolism shift towards oxidative
phosphorylation, thus leading to increased ROS production,
which may drive their entry into the cell cycle [90, 91]. An
interesting question to be addressed in the future is
whether mitochondrial ROS regulate cellular signalling
during haematopoiesis. A recent report showing that mito-
chondrial ROS downregulate Notch signalling, an event
required for HSCs differentiation [52], supports this notion.
Almost a century ago, Otto Warburg demonstrated
that tumour cells display important differences with re-
spect to their healthy counterparts in terms of the use of
glucose. Even in aerobic conditions, cancer cells produce
high amounts of lactic acid from glucose. In other
words, they rely on glucose fermentation as a way of
obtaining energy, a phenomenon known as “Warburg ef-
fect” [92]. Despite this metabolic adaptation, mitochon-
dria remain functional and tumour cells can still carry
out an oxidative phosphorylation for energy production
[93]. In fact, it is accepted that mitochondrial respiration
contributes to tumourigenesis [94]. Some authors have
identified mitochondria as the main source of ROS in
leukaemia. A recent report suggests enhanced mitochon-
drial ROS production in CML patients [70]. Moreover,
Jitschin et al. have demonstrated that increased mito-
chondrial metabolism and biogenesis correlate with ele-
vated ROS levels in CLL patients [95].
Mitochondrial DNA (mtDNA) is not packed as chroma-
tin, and therefore is more susceptible to oxidative damage
than nuclear DNA. In addition, its lack of introns
increases the probability of mutations occurring within
coding regions. As a result, an increased mitochondrial
ROS production can jeopardise the stability of mtDNA.
Concomitantly, oxidative stress could promote DNA da-
mage and mutation, which would lead to a further in-
crease in ROS production that would eventually promote
leukaemogenesis [96]. In fact, mtDNA alterations are
thought to be a risk factor for developing leukaemia, drug
resistances, and disease progression. Mutations and alter-
ations in mtDNA have been reported in the four main
types of leukaemia: CML [97, 98], AML [99], CLL [100],
and ALL [101]. More studies are needed to determine the
precise contribution of mitochondria, and their alteration,
to the oxidative stress status in leukaemia, and to dissect
the factors that increase mitochondrial ROS production.
However, the evidence accumulated so far supports the
importance of such contribution.
As will be discussed below, there are other poten-
tial sources of ROS in leukaemia. Although the
implication of ROS in this process has not yet been
proven, they have been associated with haemato-
logical malignancies. This raises the possibility that
other sources of ROS may also contribute to oxida-
tive stress in leukaemia.
Xanthine oxidoreductase (XOD) is involved in purine
catabolism and produces ROS as by-products. A high
XOD expression has been shown to correlate with
high-grade malignancy in solid tumours [102]. The
implication of XOD in leukaemia has not formally been
addressed. However, an increase of XOD activity in
AML patients has been reported [103, 104]. It is temp-
ting to speculate that this enzyme may also contribute to
oxidative stress in leukaemia.
Lipoxygenases and cyclooxygenases participate in ara-
chidonate metabolism for the production of eicosanoid
mediators. Two different studies from the same group
have recently shown the relevance of arachidonate
5-lipoxygenase (Alox5) [105] and arachidonate
15-lipoxygenase (Alox15) [106] genes for the survival of
CML leukaemia stem cells (LSC). The expression of both
genes is upregulated by BCR-ABL and is required for the
development of the disease in vivo. Although these studies
do not address whether lipoxygenases-derived ROS are re-
quired for disease onset, one could speculate about such a
possibility. Overexpression of cyclooxygenase-2 (Cox-2),
an enzyme also involved in arachidonate metabolism, has
been linked to different haematological malignancies and
is considered to be a poor prognostic factor [107].
Cytochrome P-450 enzymes (CYP) have an important
role as a detoxifying system. Certain CYP gene polymor-
phisms have been associated with a higher risk of devel-
oping different kinds of solid tumours [108]. In addition,
polymorphisms affecting CYP and other genes encoding
potential ROS sources, such as myeloperoxidase (MPO)
and NAD(P)H: quinone oxidoreductase 1 (NQO1), have
been related to a predisposition to develop ALL [109].
Antioxidant defences in leukaemic cells
As previously noted, the redox homeostasis depends on
the balance between ROS producers and cellular antioxi-
dant systems. A defective antioxidant defence could
account for the increased levels of ROS detected in leu-
kaemic cells. Indeed, this fact has been observed in both
myeloid and lymphoid leukaemias. The activity of several
antioxidant enzymes was reduced in CML patients [110].
Furthermore, the presence of an impaired antioxidant de-
fence system has recently been reported in AML patients
[111]. The level of antioxidant enzymes, such as gluta-
thione peroxidase, catalase and superoxide dismutase, is
reduced in ALL patients [74]. Moreover, a decrease in the
activity of catalase and superoxide dismutase, together
with a lower level of reduced glutathione, has been
detected in CLL samples [112].
Therefore, a diminished cellular antioxidant capacity
may explain the oxidative stress found in leukaemic
cells; however, this is not a general statement. In fact,
the antioxidant capacity is often increased in leukaemia
patient cells [113]. Depending on the scenario, certain
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antioxidant enzyme levels could be increased or
decreased. The down-modulation of some antioxidant
systems would contribute to the high level of ROS found
in these cells, while the upregulation of other systems
would allow the cells to survive under a situation of per-
manent oxidative stress without surpassing a deadly
threshold. In other words, modulation of antioxidant
defences allow leukaemic cells to increase their redox
signalling without setting in motion an irreparable state
of oxidative stress [113].
Leukaemic oncogenes induce ROS production
Genetic alterations caused by chromosomal transloca-
tions or activating mutations are observed in several
leukaemia-related oncogenes. Recent evidence shows
that some of these changes are able to induce ROS pro-
duction, which could be an important driving force for
leukaemogenesis.
BCR-ABL is probably one of the best examples of
leukaemia-driving oncogenes; the expression of the
chimeric BCR-ABL tyrosine kinase is sufficient for cell
transformation in CML [114]. Several reports support the
idea that BCR-ABL is able to induce ROS production
from different sources, including mitochondria [115], the
upregulation of NADPH oxidase activity [116] by increas-
ing p47Phox expression [117] and an enhanced glucose
metabolism [118]. It seems that the increased ROS
production would be important for cell growth and trans-
formation. The oxidative stress would increase genomic
instability and mutagenesis [119]. This vicious circle of
oxidative stress-DNA mutation could affect the BCR-ABL
gene itself, causing the occurrence of BCR-ABL protein
variants resistant to the standard tyrosine kinase inhibitors
(TKi) used in clinical practice [120]. About 30% of AML
patients exhibit internal tandem duplications in the
FMS-like tyrosine kinase-3 (FLT3) receptor, giving rise to
the FLT3/ITD oncokinase [121]. FLT3/ITD induces ROS
production through NADPH oxidases [122], which has
been suggested to contribute to leukaemic transformation
[121, 123]. Activating mutations in either NRAS or
KRAS genes occur in AML, juvenile myelomonocytic
leukaemia (JMML), chronic myelomonocytic leukaemia
(CMML) [124], childhood ALL [125] and myelodysplas-
tic syndromes (MDS) [126]. It has long been known
that cell transformation by RAS relies on NADPH
oxidase-driven ROS production [127], which induces
growth factor-independent proliferation of human
CD34+ cells [128]. Thus, it has been proposed that
Ras-dependent ROS production could contribute to
leukaemogenesis [126].
The activating mutation of JAK2V617F often appears in
MPNs [129]. Recent reports detected an increased ROS
production in MPNs carrying the JAK2V617F mutation,
as a consequence of NADPH oxidase activation [75] or
catalase downregulation [130]. Experimental evidence
supports the hypothesis that increased ROS production
in the HSC compartment would contribute to MPN
progression [130].
All the examples of oncogenes analysed so far encode
proteins that activate signal transduction pathways
driven by protein phosphorylation. It is intriguing that in
all these cases the activation of NADPH oxidases
contributes to increased ROS production. Although
there are other mechanisms through which these onco-
genes may enhance ROS generation, it is reasonable to
consider the activation of NADPH oxidases as the most
likely cause. Thus, oxidation-mediated PTP inactivation
and subsequent boosting of phosphorylation cascades
driven by oncogenes through this mechanism could be
proposed.
The FIP1L1-PDGFRA fusion gene, which leads to the
constitutive activation of PDGF receptor, is the most fre-
quent genetic defect in hypereosinophilic syndrome
(HES), and has been found in approximately 50% of
chronic eosinophilic leukaemia (CEL) patients. The
expression of this kinase has been associated with the
down-regulation of different antioxidant enzymes; thus,
suggesting an increase in ROS could be a possible onco-
genic factor in this kind of leukaemia [131].
Mutations of the Isocitrate dehydrogenase 1 (IDH1)
and 2 (IDH2) genes have been recently found to be com-
mon in AML [132]. Most of them are gain-of-function
mutations. Instead of oxidising isocitrate to
α-ketoglutarate (α-KG), rendering NADPH, the mutant
enzymes reduce α-KG to 2-hydroxyglutarate (2-HG)
with the consumption of NADPH [133]. These
mutations alter redox homeostasis, first by diminishing
cellular NADPH content, and then because 2-HG acts
as an oncometabolite that contributes to leukaemia
transformation by increasing oxidative stress [134].
The use of ROS as a therapeutic target in
haematological malignancies
The permanent condition of the oxidative stress of leu-
kaemic cells may offer interesting therapeutic options, and
as a result the possibility of developing redox chemothera-
peutics has received much more attention in recent years
[135, 136]. In this regard, increasing or decreasing ROS
levels may provide a suitable global strategy against leu-
kaemia (Fig. 2 and Table 1). Theoretically, a pro-oxidant
treatment could lead to an unbearable situation of oxida-
tive stress incompatible with the viability of leukaemic
cells. Conversely, the reduction of ROS levels could also
be a feasible option due to the importance of ROS in sus-
taining leukaemic cell proliferation and survival. The
lower levels of ROS detected in healthy cells could offer a
certain type of specificity that would allow these cells to
survive or become less affected.
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Increasing oxidative stress contributes to the mechanism
of action of anti-leukaemia chemotherapeutics
This section will discuss how some front-line
anti-leukaemia chemotherapeutics alter the cellular
redox balance, which could be important for their
pharmacologic effect. A better understanding of this
question would help to improve their therapeutic effect
and overcome drug resistance.
AML still presents a great therapeutic challenge, of
which the initial treatment cycle consists of arabinocyto-
sine (a.k.a. cytarabine), a purine analogue that interferes
with DNA replication, during 7 days, followed by
anthracyclines antibiotics for 3 days. This is followed by
additional chemotherapy or transplantation [137]. An
increase in intracellular ROS has been found to be asso-
ciated with the mechanism of action of cytarabine [138].
In this study the source of ROS was identified as coming
from mitochondria. However, as reviewed elsewhere
[139], anthracyclines could induce ROS formation via
other mechanisms: (i) interacting with free iron and (ii) as
by-products of their own metabolism by enzymes such as
cytochrome P450 reductase, NADH dehydrogenase or
XO and thioredoxin reductase (TrxR) [138]. NADPH
oxidases are also implicated in anthracyclines-induced
increase of ROS [140–142]. A recent study related the effi-
cacy and toxicity of anthracyclines to NADPH oxidase
polymorphisms [143]. The importance of ROS in the
mechanism of action of anthracyclines was also
highlighted by the fact that administration of antioxidants
reduced their cytotoxicity [144]. In addition, it has been
suggested that the enhancement of cellular antioxidant
systems, such as SOD2 [145] or glutathione [146], could
drive resistance to anthracyclines.
There is a significant number of novel compounds for
AML treatment, whose feasibility is currently being tested
in clinical trials [137]. Interestingly, the mechanism of
Fig. 2 Redox-based treatment of haematological malignancies. The diagram shows three different approaches relying on ROS modulation of
leukaemic cells: increasing ROS either upon stimulation of their cellular sources or inhibition of the antioxidant systems, in order to exceed the
amount compatible with life, and decreasing the ROS, mainly by inhibition of cellular sources, thereby depleting the proliferative advantage that
these products provide to the cancer cell. Some examples of drugs or plausible therapeutic strategies and their cognate cellular targets illustrate
the three approaches described (see text for details). Dotted arrows with question marks indicate plausible but not completely established
mechanisms of action
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action of some of these agents might be related to the al-
teration of redox homeostasis. Enzymes that control DNA
epigenetic modifications, such as histone deacetylases
(HDACs), are among their targets. HDACs inhibitors
(HDACi), such as vorinostat, show anti-tumour capacity
and increase ROS production. The use of antioxidants
consistently reduces HDACi cytotoxicity [147], thus
suggesting the importance of increased ROS production
in the mechanism of action of HDACi. In addition, there
is a study showing that AML cells resistant to HDACi
exhibit higher antioxidant defences [148]. The aforemen-
tioned increase in ROS may be derived from mitochondria
[147] and NADPH oxidases [148]. The mechanism of ac-
tion of other epigenetic enzyme inhibitors currently being
Table 1 Chemotherapeutics that alter cellular redox balance
Compound Status ROS modulation Clinical Trials
Arsenic trioxide
(As2O3, trisenox)
FDA-approved for the treatment
of relapsing AML.
↑ ROS:
Inhibits MRC, TrxR and SOD;
induces the expression of
Nox2 complex genes and
depletes Prx III
Phase II study of As2O3 plus decitabine and
cytarabine AML with p53 mutations
(NCT03381781, not yet recruiting).
Phase I studies of As2O3 plus decitabine
(NCT00671697, completed in 2011), plus
cytarabine and idarubicin (NCT00093483,
completed in 2009) for AML treatment.
Phase II/III study of As2O3 plus altezumab
and other chemoteraputic agents for AML
or MDS treatment (NCT00454480, completed).
Metformin FDA-approved for the treatment




Phase II study for CLL treatment
(NCT01750567, recruiting).
Phase I study of metformin plus ritonavir
for relapsed/refractory MM or CLL treatment
(NCT02948283, active).
Phase I study for relapsed childhood ALL
(NCT01324180; completed).
Phase I study of metformin plus cytarabine
for relapsed/refractory AML treatment
(NCT01849276, active).






Phase I study for AML treatment
(NCT01332786, completed in 2015).
In vitro study of tigecycline in cells from CML
patients (NCT02883036, not yet
recruiting).
NOV-002 Under clinical trial. ↑ ROS:
GSSG mimetic
Phase III study of NOV-002 plus cis-platinum
and placlitaxel for NSCLC treatment
(NCT00347412, completed in 2010).
2-methoxyestradiol
(2-ME, panzem)
FDA-approved for ovarian cancer,
metastatic malignant melanoma,
MM and pancreatic adenocarcinoma.
↑ ROS:
SOD inhibitor
Phase II study for the treatment of relapse
or plateau phase myeloma (NCT00592579,
completed in 2008).






Phase I/II study in MM (NCT00327249,
completed in 2008).
Phase II study for the treatment of aggressive
lymphomas (NCT01314014, completed in 2014).
ATN-224 Under clinical trial. ↑ ROS:
SOD inhibitor
Phase I/II study of ATN-224 plus bortezomib
in MM patients (NCT00352742, completed
in 2008).
PX-12 Under clinical trial. ↑ ROS:
Thioredoxin system
inhibitor
Phase I (NCT00736372, completed in 2009)
and phase II studies (NCT00417287, completed




Under clinical trial. ↑ ROS:
Export GSH outside
of the cell and inhibits
GPx
Phase I study for preventing lung cancer
(NCT00005883, completed).
PEITC as support care in head and neck cancer
patients (NCT03034603, recruiting).
GKT137831 Under clinical trial. ↓ROS:
NOX1 and NOX4 inhibitor
Phase II study for the treatment of patient with
type 2 diabetes (NCT02010242, completed
in 2015).
Allopurinol FDA-approved for gout treatment





Phase II study of allopurinol in pediatric
ALL treatment to improve 6-mercaptopurine
treatment (NCT03022747, recruiting).
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tested for AML treatment, such as Lysine-specific
demethylase 1 (LSD1) [149] and Bromodomain and
Extra-Terminal proteins (BET) inhibitors [150], could also
be related to increases in ROS.
The cell cycle is another interesting molecular target
in AML and cyclin-dependent kinases (CDKs) inhibitors
are currently being studied in this respect [137]. Some
work supports the fact that the antiproliferative effect of
this type of inhibitors is linked to the induction of oxida-
tive stress [151].
Leukaemic cells have a high concentration of ubiquiti-
nated proteins [152]. Therefore, a number of proteasome
inhibitors have been tested for anti-leukaemic activity.
The first proteasome inhibitor approved by the FDA,
bortezomib, has shown effectiveness against multiple
myeloma (MM) [153], and it could also be used for
AML [154] or CLL [155] treatment; induced oxidative
stress is important for bortezomib cytotoxicity [156].
The treatment of acute promyelocytic leukaemia (APL)
with the pro-differentiation agent all-trans retinoic acid
(ATRA) is an effective strategy that would be interesting
to treat other types of leukaemia [157]. In cases of re-
lapsed APL, arsenic trioxide (As2O3, Trisenox) is a good
drug choice, as it has been approved by the FDA against
this disease in combination with ATRA and anthracyclines
chemotherapy. Currently, As2O3 efficacy is being tested in
newly diagnosed APL patients, with complete remission
in 83–86% of patients and 3-year overall survival. As2O3
acts through different mechanisms such as stimulation of
differentiation, induction of apoptosis, and NF-κB inhib-
ition [158]. However, it seems that its main effect would
be the induction of ROS accumulation. As2O3 can alter
the cellular redox homeostasis at different levels: (i) by in-
ducing electron leakage from the mitochondrial respira-
tory chain [159] and (ii) through the expression of the
genes that code for the Nox2 complex-forming proteins
[160]. As suggested by the irreversible inhibition of TrxR
[161] and the depletion of peroxiredoxin III (Prx III)
[162], As2O3 may also diminish the cellular antioxidant
capacity, which would contribute to raise ROS levels. It is
noteworthy that As2O3 cytotoxicity inversely correlates
with the level of glutathione [163]. This is of key rele-
vance, since the measurement of antioxidant defences in
patient samples could help to predict their responsiveness
to As2O3 or other pro-oxidant treatments, as previously
reported for paclitaxel, a chemotherapeutic that also
increases ROS [164]. This information could also help to
improve the effect of As2O3, by simultaneously targeting
various antioxidant cellular systems. In this regard, the re-
duction of glutathione has shown to increase the effective-
ness of As2O3 [165]. Jeanne et al. have shown the
importance of ROS production in the molecular mecha-
nism of action of As2O3. The oxidative stress induced by
As2O3 allows for PML/RARα dimerization through the
formation of a disulfide bridge. Direct binding of As2O3 to
PML/RARα dimers induces the formation of multimers
and their association with the nuclear matrix in the
so-called nuclear bodies (NBs), where eventually sumoyla-
tion and degradation of PML/RARα occurs [166].
A striking observation is that, despite differences
between the mechanisms of action of all the previously
described chemotherapeutics, they share oxidative stress
as a mediator of their cytotoxic activity. This implies
that in the past leukaemia was unintentionally targeted
through redox mechanisms. The awareness of this fact
may have important practical consequences, since it
could help to improve therapeutic results, overcome
resistances and reduce toxic side effects. Regarding the
latter issue, the use of the tubulin inhibitor vincristine to
treat ALL is associated with neurotoxicity [167]. The
experimental evidence suggests that the cytotoxicity of
vincristine and other tubulin inhibitors, such as pacli-
taxel, is related to the induction of oxidative stress [168].
Importantly, the concomitant use of antioxidant mole-
cules reduced the toxic side effects of paclitaxel and
other chemotherapeutics without compromising, or even
improving, therapeutic results [169].
Given the complexity of leukaemia and the multiple
factors contributing to its development, single-agent
treatments are sometimes not satisfactorily effective;
thus, combinatorial treatments are very common. The
combination of two of the previously mentioned chemo-
therapeutics would ensure that two different biological
processes relevant to leukaemic cells were targeted.
Additionally, the combined treatment would increase
oxidative stress (Table 1). Preclinical studies in leu-
kaemic cell lines have shown a synergistic effect when
combining HDACi with proteasome inhibitors, which is
dependent on ROS production [170]. This result has led
to two recently conducted phase II clinical trials in
which the combination of bortezomib with vorinostat
was tested in AML (NCT00818649) and ALL
(NCT01312818). The combination of As2O3, bortezomib
and L-ascorbate was recently evaluated in a clinical trial
against relapsed or refractory MM with encouraging
results [171]. Recent clinical trials have tested the
combination of As2O3 with other compounds that also
can increase ROS levels in AML patients. Examples are
decitabine (NCT00671697, Phase I; NCT03381781,
Phase II); citarabine and idarubicin (NCT00093483,
Phase I); combination of altezumab with As2O3 and
other chemotherapeutics (NCT00454480, Phase II/III).
The ongoing search for novel chemotherapeutics that
increase ROS levels
Given the oxidative stress “addiction” displayed by
cancer cells, the promotion of their death through a
ROS “over-dose” is becoming a popular idea. The
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realisation that many chemotherapeutics increase the
oxidative stress has paved the way for the active search
for novel compounds that can increase ROS levels, as
recently reviewed [135]. Although some of these
compounds may not be very effective as single agents,
some reports suggest that they could potentiate the
effect of traditional therapy and help to overcome
resistance [172].
In the search for agents that alter cellular redox
homeostasis, the mitochondrion should be one of the
first targets considered. As reviewed elsewhere, the use
of mitochondrial inhibitors is a suitable strategy for in-
ducing oxidative stress with a therapeutic purpose in
leukaemic cells [94]. Moreover, mitochondrion-targeting
drugs might also activate the intrinsic apoptotic path-
way. Interestingly, metformin, an antidiabetic drug, has
been shown to inhibit mitochondrial ATP production
and increase ROS [173]. This drug is currently under
study in clinical trials for CLL (NCT01750567, phase II;
NCT02948283, phase I), relapsed childhood ALL
(NCT01324180, phase I), and relapsed/refractory AML
(NCT01849276, phase I). Adaphostine, initially de-
scribed as a TKi, increases ROS levels by inhibiting
mitochondrial respiration [174], and can overcome re-
sistance against imatinib in primary CML cells [175].
The safety of tigecycline, an antibiotic that inhibits mito-
chondrial biogenesis, has already been tested in AML
patients (NCT01332786, Phase I) [176]. An in vitro
study on the anti-leukaemic effect of tigecycline against
cells from CML patients (NCT02883036) is also
scheduled.
A recent report has shown the importance of limiting
ROS production by cellular antioxidant defences for can-
cer initiation [177]. This work revealed that glutathione
and thioredoxin are required for tumour initiation, and
that inhibition of these antioxidant systems hinders
tumour growth in a synergistic manner. This evidence
strongly suggests that targeting the cellular antioxidant
defences is an interesting strategy for fighting against
tumour cells. In line with this, there is a growing list of
preclinical studies testing the anti-tumour capacity of in-
hibitors for different antioxidant cellular systems, some
of which will be discussed below.
The glutathione/glutathione peroxidase (GSH/GPx)
system is a major regulator of redox homeostasis; there-
fore, its impairment may induce a severe oxidative stress
in the cells. NOV-002, a complex of oxidised glutathione
(GSSG) with cisplatin in a ratio of 1000:1, has shown ef-
fectiveness against non-small cell lung cancer (NSCLC)
(NCT00347412, Phase III). Imexon acts by depleting
glutathione levels [178]. Recent clinical trials have tested
imexon in MM (NCT00327249, phase I/II) and aggres-
sive lymphomas (NCT01314014, phase II). Similarly,
glutathione depletion by buthionine sulfoximine (BSO)
activates apoptosis in ALL cells [179] and increases
As2O3 activity [180], suggesting that the use of this type
of compounds to treat leukaemia could be an interesting
option.
Different SOD inhibitors, such as ATN-224 [172] or
2-methoxyestradiol (2-ME, panzem) [181], have shown
anti-leukaemic capacity in preclinical studies. Interestingly,
a recent report has identified 2-ME as capable of targeting
T-ALL pre-leukaemic stem cells without affecting normal
HSCs in a high-throughput screening [182]. Recent clinical
trials have tested the combination of ATN-224 and borte-
zomib in MM patients (NCT00352742, phase I/II), and
2-ME for targeting relapse or plateau phase myeloma
(NCT00592579, phase II).
A conceptually opposing strategy could be proposed on
the basis of some reports showing that SOD inhibits can-
cer cell growth. [183]. With this respect, the use of SOD
mimetics in combination of other chemotherapeutics that
increase ROS against cancer is being assessed [184]. These
compounds may have antioxidant activity by decreasing
superoxide levels, despite the fact that they can also in-
crease the cellular level of H2O2. There is strong evidence
supporting the idea that these mimetics would preferen-
tially target highly dividing tumour cells, thus potentiating
the effectiveness of other chemotherapeutics and reducing
their toxic side effects as shown by a recent clinical trial
(NCT00727922) [185].
Another body of research suggests that the thiore-
doxin redox system is an interesting drug target in
cancer [186]. Several molecules interfere with this
system, and some of them, such as PX-12 [187],
gliotoxin [188], and chaetocin [189], have shown
anti-leukaemic effects in preclinical studies. Recent
clinical trials have tested PX-12 against solid tumours
(NCT00736372, NCT00417287).
The heme oxygenase enzyme-1 (HO-1) catalyses
the degradation of heme group to ferrous iron, bili-
verdin and carbon monoxide (CO). Under oxidative
stress, HO-1 expression is induced by the NRF2
transcription factor as part of the cellular antio-
xidant defence response. HO-1 is upregulated in
some leukaemic cells [190], which could be a com-
pensatory mechanism to cope with oxidative stress
[95]. It is noteworthy that HO-1 overexpression has
been related to drug resistance [191]. There is ex-
perimental evidence showing that targeting HO-1
may be an interesting strategy to i) fight haemato-
logical malignancies, and ii) overcome the resistance
to pro-oxidant drugs [190].
As previously mentioned, the activity of many tran-
scription factors is inhibited by oxidation, where APE/
Ref-1 catalyses the reduction of several of them [19].
APE/Ref-1 inhibition induces sensitivity to anti-tumour
drugs [192]. This finding, as well as the development of
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several APE/Ref-1 inhibitors [193], suggests that this
protein could be a promising therapeutic target in the
treatment of leukaemia [192].
Another line of work in the search for pro-oxidant
chemicals is testing the anti-tumour activity of natural
derivatives, as some, such as parthenolide, triptolide and
avocatin B, have shown effectiveness against AML cells
[194]. Phenethyl isothiocyanate (PEITC), a compound
present in cruciferous vegetables, has made a stellar
apparition in the field of cancer therapeutics. There is a
vast number of preclinical studies revealing the
anti-tumour activity of PEITC, which is related to the in-
duction of ROS [195]. Experimental evidence suggests
that PEITC may increase sensitivity to chemotherapy in
B-cell prolymphocytic leukaemia (B-PLL) patients [196],
and overcome resistance in CLL [197] and CML [198].
Recent (NCT00005883, Phase I) and ongoing
(NCT03034603) clinical trials will elucidate the potential
benefit of using PEITC as a nutritional supplement
against cancer.
Natural flavonoids can work either as ROS scavengers
or pro-oxidants. Several preclinical reports showed that
some natural flavonoids and their derivatives have
pro-apoptotic and cytotoxic effects against different
types of haematological malignancies. Interestingly,
many of the anti-leukaemic effects described in the lit-
erature for these compounds are linked to an increase in
oxidative stress [199].
Reducing ROS levels as a chemotherapeutic strategy
It can be suggested that reducing ROS levels may restrain
the development of these diseases, given the high degree
of oxidative stress typical of haematological malignancies.
In spite of this, and as discussed above, during the last
decade most efforts have been made to kill tumour cells
by a ROS overload. In this regard a common assumption
is that an antioxidant-rich diet might reduce the incidence
of leukaemia. However, the benefit of the antioxidants
used during the oncologic treatment is a matter of debate.
Some reports show that antioxidants can reduce the
cytotoxicity of many chemotherapeutics. Taking this into
account, it could be suggested that the use of antioxidants
during an oncologic treatment would be unadvisable.
However, there is also evidence showing that antioxidants
could reduce the toxic side effects caused by pro-oxidant
drugs [200]. Therefore, the use of antioxidants as adju-
vants of oncologic treatments indeed requires further
evaluation to discover the way in which therapeutic
benefits can be attained [201].
An alternative to ROS-scavengers could involve the
inhibition of the source(s) of ROS production, whose
identification and further inhibition would be more ef-
fective than the use of antioxidants. As discussed above,
NADPH oxidases could be one of the sources of ROS in
leukaemic cells. In addition, the over-expression of some
genes related to chemotherapeutic resistance, such as
HO-1, is under NADPH oxidases control [202]. Consi-
dering this, NADPH oxidases appear to be suitable
therapeutic targets in leukaemia. Preclinical data show
that the inhibition of NADPH oxidases is an effective
strategy to block the signalling cascades initiated by the
BCR-ABL and FLT3-ITD oncokinases in CML and AML
cells, respectively. This evidence supports the hypothesis
that the aforementioned proteins induce NADPH
oxidase-driven ROS production to maintain the signal-
ling cascade fully active. Thus, the use of TKis and
NADPH oxidase inhibitors presents a strong synergistic
effect [81]. As discussed above, several oncogenes
increase ROS production through NADPH oxidases,
which turns these enzymes into desirable targets against
leukaemia. However, the development of novel and more
specific inhibitors against NADPH oxidases is still a
challenge [203]. The safety and efficacy of two novel
NADPH oxidases inhibitors (GKT136901 and
GKT137831) have been tested in diabetic patients
(NCT02010242). Once the suitability of these agents is
demonstrated, their use could be extended to the treat-
ment of certain types of leukaemia.
The inhibition of ROS production by XOD is another
possibility for targeting leukaemic cells. Allopurinol, a
XOD inhibitor currently prescribed to gout patients, has
been considered since almost 50 years ago for the
treatment of haematological malignancies [204]. In
addition to modifying ROS levels, XOD is involved in
the metabolism of several drugs. Recent reports suggest
the utility of allopurinol to reduce chemotherapy toxicity
in leukaemia patients [205]. An ongoing clinical trial is
testing the feasibility of allopurinol to improve
6-mercaptopurine regimen in paediatric ALL treatment
(NCT03022747, phase II).
IDHs mutations in AML patients induce an increase
in ROS [206], and the use of IDH inhibitors can be seen
as a promising strategy against AML [207]. Thus, some
interesting questions to be addressed in future studies
are whether these inhibitors have the ability to reduce
the oxidative stress in leukaemic cells, and whether their
anti-tumour activity may be increased by the use of
other ROS-modifying agents.
Practical implications for the haematopoietic transplant
Allogenic BM transplantation has been considered for
decades as a good therapeutic option for different
haematological diseases [208]. As a result, improving
transplant outcome is of great importance. Although
HSCs live in a low oxygen concentration niche, which
limits the generation of ROS, the collection of donor
HSCs is carried out under atmospheric conditions and
could lead to the abrupt increase of ROS. Moreover,
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mobilization of HSCs in response to G-CSF is a common
strategy for collecting human HSPCs. However, this
mobilization occurs with an increase in ROS [209]. Given
the importance of redox homeostasis to regulate HSCs
quiescence and differentiation, it could be assumed that
the limitation of ROS generation in transplantable HSCs
would improve their reconstitution capacity.
There is a well-designed study conducted in an animal
model showing that the collection of HSCs in hypoxic
conditions significantly enhances transplant efficacy
[210]. Furthermore, it has been recently described that
the increase of ROS in HSCs correlates with a poor en-
graftment [211]. Therefore, it could be hypothesised that
pharmacological mitigation of the accumulation of ROS
could be also an interesting strategy to improve BM
transplantation. In fact, a recent report shows that
limiting mitochondrial oxidative stress with a MnSOD
mimetic improves the function of HSCs in animal
models of haematopoietic transplantation [212]. These
findings encourage further studies for improving trans-
plantation through modulation of ROS levels.
Conclusions
The importance of ROS for the control of cellular sig-
nalling and gene expression is already a fully accepted
concept. The level of ROS must be strictly regulated to
control the biology of HSCs, suggesting the importance
of redox signalling in haematopoiesis. Cancer cells, in-
cluding leukaemic cells, live under oxidative stress and it
is considered that an excessive level of ROS can con-
tribute to proliferation and cell transformation. The po-
tential sources of oxidative stress in leukaemic cells have
been reviewed. The high level of ROS found in
leukaemic cells certainly provides them with some ad-
vantages over healthy cells. However, this is a dangerous
pathway, since, as already discussed, the alteration of
ROS levels can jeopardise leukaemic cell proliferation
and viability. The search for novel therapeutic strategies
that either increase or reduce ROS levels represents an
interesting approach to combat leukaemia. Moreover,
there are different chemotherapeutic agents for treating
leukaemia that are currently used in clinical practice
whose activity relies on changes in the levels of ROS.
This condition should be exploited in order to boost
their activity.
Finally, given the importance of ROS for the control of
HSCs biology, the modulation of ROS levels as a power-
ful strategy to improve the haematopoietic transplant is
also proposed. Details regarding the involvement of ROS
in haematopoiesis and leukaemogenesis are slowly be-
ginning to be revealed. Future studies should be focused
on defining the sources of ROS and their targets in
haematopoiesis, which undoubtedly will help clinicians
to improve the health of haematological patients.
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